Brokerages Set Definitive Healthcare Corp. (NASDAQ:DH) PT at $5.10

Shares of Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) have been assigned an average rating of "Reduce" from the ten ratings firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $5.10.

A number of analysts recently weighed in on the stock. The Goldman Sachs Group raised their target price on shares of Definitive Healthcare from $3.00 to $3.40 and gave the stock a "neutral" rating in a report on Monday, May 12th. BTIG Research cut shares of Definitive Healthcare from a "buy" rating to a "neutral" rating in a report on Friday, May 9th. Finally, Wall Street Zen raised shares of Definitive Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, June 21st.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DH. Goldman Sachs Group Inc. boosted its position in shares of Definitive Healthcare by 564.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company's stock valued at $25,191,000 after acquiring an additional 7,404,363 shares in the last quarter. Whetstone Capital Advisors LLC acquired a new stake in shares of Definitive Healthcare during the 1st quarter valued at about $2,512,000. Irenic Capital Management LP lifted its holdings in Definitive Healthcare by 9.2% during the 4th quarter. Irenic Capital Management LP now owns 7,003,194 shares of the company's stock valued at $28,783,000 after purchasing an additional 590,009 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Definitive Healthcare during the 4th quarter valued at about $1,181,000. Finally, Two Sigma Investments LP lifted its holdings in Definitive Healthcare by 2,383.1% during the 4th quarter. Two Sigma Investments LP now owns 285,555 shares of the company's stock valued at $1,174,000 after purchasing an additional 274,055 shares during the last quarter. 98.67% of the stock is currently owned by institutional investors and hedge funds.

Definitive Healthcare Stock Performance

Shares of NASDAQ:DH traded down $0.18 during trading hours on Thursday, hitting $3.84. The stock had a trading volume of 424,089 shares, compared to its average volume of 810,960. The stock's fifty day simple moving average is $3.68 and its 200 day simple moving average is $3.63. Definitive Healthcare has a 1-year low of $2.15 and a 1-year high of $6.16. The firm has a market capitalization of $570.79 million, a price-to-earnings ratio of -0.87, a PEG ratio of 6.46 and a beta of 1.64. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. The business had revenue of $59.19 million during the quarter, compared to analysts' expectations of $56.20 million. Definitive Healthcare had a negative net margin of 206.05% and a positive return on equity of 3.69%. The business's revenue was down 6.8% on a year-over-year basis. During the same period last year, the firm posted $0.08 earnings per share. Sell-side analysts anticipate that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.